US NTM Delayed Up to 12 Months; Cowen Cuts Price Target on Insmed (INSM) to $34
Cowen reiterated an Outperform rating on Insmed (NASDAQ: INSM), and cut the price target to $34.00 (from $38.00), folloiwng the ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)